Pfizer and biontech advance next-generation covid-19 vaccine strategy with study start of candidate aimed at enhancing breadth of t cell responses and duration of protection

New york and mainz, germany, november 16, 2022 — pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced that the companies have initiated a phase 1 study to evaluate the safety, tolerability and immunogenicity of a next generation covid-19 vaccine candidate that aims to enhance sars-cov-2 t cell responses and potentially broaden protection against covid-19. this candidate, bnt162b4, is composed of a t cell antigen mrna encoding for sars-cov-2 non-spike proteins that are highly conserved across a broad range of sars-cov-2 variants and will be evaluated in combination with the companies' omicron ba.4/ba.5-adapted bivalent covid-19 vaccine. these non-spike proteins have been chosen based on biontech's proprietary target prioritization platform and were designed into a vaccine candidate with the purpose of enhancing and broadening t cell immunity and potentially extending durability of protection against covid-19.
BNTX Ratings Summary
BNTX Quant Ranking